Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls

• DOI: 10.5812/ijem.23085v2
• Publication Date: 2015-06-30T07:54:41Z
• Authors: Kobra Shiasi Arani; Fatemeh Heidari
• Keywords: Triptorelin; Central precocious puberty; Gonadotropin-releasing hormone agonist; Menarche; Leuprorelin

Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for treatment central precocious puberty. A concern about these is obesity.This study aimed to investigate effect therapy on body mass index (BMI) in girls with puberty (CPP).The onset before eight years age or menarche nine were studied. The weight, height, BMI, and pubertal stage determined at sixth 12th months treatment. GnRHa (Triptorelin) was administered intramuscularly patients rapidly progressive forms CPP. Patients slowly CPP considered as control group.From 110 subjects CPP, 46 (41.8%) intervention 64 (58.2%) groups. mean initial visit 7.46 ± 1.03 years. BMI deviation scores both groups not significantly different compared baseline (P = 0.257 P 0.839, respectively). prevalence obesity between 0.11, 0.068, 0.052, respectively).The has no obesity.